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Decline of motor performance is an important 
feature of the aging process. Walking speed is 
a reliable measure of functional mobility and 
motor performance in elderly people and has 
been associated with adverse health effects, 
including falls, late­life disability, hospital 
admissions, and mortality (Dumurgier et al. 
2009; Kuo et al. 2006b). Cognitive func­
tion, particularly executive function, appears 
intimately connected with motor function 
(Hausdorff et al. 2005; Rosano et al. 2005; 
Sheridan et al. 2003). There is increasing evi­
dence that vascular risk factors (hypertension) 
(Dumurgier et al. 2010), metabolic condi­
tions (diabetes) (Ko et al. 2011), and mark­
ers of subclinical atherosclerosis (Brunner 
et al. 2011; Elbaz et al. 2005) are negatively 
associated with motor performance, which 
is thought to be a result of their effects on 
the nervous system, such as increases in white 
matter lesions (Soumare et al. 2009a).
Lead is detrimental in many aspects of 
human health. Even at general environmen­
tal exposure levels, lead exposure is associ­
ated with lower IQ during neurodevelopment 
(Lanphear et al. 2005) and impaired cogni­
tive function among adults (Bandeen­Roche 
et al. 2009; Shih et al. 2006, 2007; Weisskopf 
et al. 2007; Weuve et al. 2009). In addi­
tion, there is some evidence of an association 
between Parkinson’s disease and lead expo­
sure (Weisskopf et al. 2010). Neurological 
consequences of lead exposure may be attrib­
utable to direct neurotoxic effects on the 
vascular system, including hypertension and 
cardiovascular disease, or through effects on 
diabetes and poor renal health (Menke et al. 
2006; Navas­Acien et al. 2007; Schober et al. 
2006; Weisskopf et al. 2009).
Given the neurological and vascular tox­
icities of lead (Baker et al. 1979; Menke et al. 
2006; Navas­Acien et al. 2007; Schober et al. 
2006; Shih et al. 2007; Tsaih et al. 2004; 
Weisskopf et al. 2009, 2010) and the asso­
ciation between occupational lead exposure 
and neuromuscular function (Baker et al. 
1979; Bleecker et al. 2007; Weisskopf et al. 
2004), we wanted to explore whether lead 
exposure at general environmental exposure 
levels could adversely affect walking speed. 
We therefore studied the cross­sectional rela­
tion between walking speed and blood lead 
concentration among participants in the 
National Health and Nutrition Examination 
Survey (NHANES), a population of ran­
domly selected civilian, noninstitutionalized 
residents across the United States.
Methods
Study population. Beginning in the 1960s, 
the National Center for Health Statistics 
conducted a series of cross­sectional health 
and nutrition surveys known as the National 
Health and Nutrition Examination Survey 
(NHANES). The NHANES study proto­
col is described in detail elsewhere (Centers 
for Disease Control and Prevention 2012). 
In brief, NHANES uses a complex, multi­
stage probability sampling design, with over­
sampling of adolescents 12–19 years of age, 
adults ≥ 60 years of age, low­income per­
sons, Mexican Americans, and non­Hispanic 
blacks. All participants completed household 
surveys conducted by trained study staff, 
which include questions about demographics 
and health history. The study protocol also 
includes standardized medical examinations, 
collection of a blood sample, and other in­
person testing at mobile examination cen­
ters. Informed consent was obtained from all 
NHANES participants.
For the present study we used publicly 
available NHANES data from the 1999–
2000 and 2001–2002 surveys, in which 
time to walk 20 ft (at usual walking pace) 
was measured in participants ≥ 50 years of 
age. We excluded participants (n = 230) who 
had had a myocardial infarction in the pre­
ceding 6 weeks; chest or abdominal surgery 
within the preceding 3 weeks; a history of 
brain aneurysm or stroke, knee surgery or 
knee replacement, or severe back pain; used 
an assistive device during walking speed 
measurement; or had Parkinson’s disease or 
reported taking Parkinson’s medication. We 
also excluded four people with improbably 
high walking speed (> 6 ft/sec). Our final 
sample for blood lead and walking speed con­
sisted of 1,798 women and 1,795 men. Our 
study was deemed exempt from full review 
by the Institutional Review Board of the 
Harvard School of Public Health.
Blood lead assessment. We determined 
blood lead concentration using atomic absorp­
tion spectroscopy on a PerkinElmer Model 
SIMAA 6000 while employing Zeeman 
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Background: Walking speed is a simple and reliable measure of motor function that is negatively 
associated with adverse health events in older people, including falls, disability, hospital admissions, 
and mortality. Lead has adverse affects on human health, particularly on the vascular and neuro-
logical systems.
oBjective: We explored the hypothesis that lead is associated with slower walking speed.
Methods: We used U.S. National Health and Nutrition Examination Survey (NHANES) cross-
sectional data from 1999–2002. The time to walk 20 ft (walking speed) was measured among 1,795 
men and 1,798 women ≥ 50 years of age. The association between walking speed and quintiles of 
blood lead concentration was estimated separately in men and women using linear regression models 
adjusted for age, education, ethnicity, alcohol use, smoking status, height, and waist circumference.
results: Mean blood lead concentrations and walking speeds were 2.17 µg/dL and 3.31 ft/sec in 
women, and 3.18 µg/dL and 3.47 ft/sec in men, respectively. Among women, walking speed decreased 
with increasing quintiles of blood lead, resulting in an estimated mean value that was 0.11 ft/sec 
slower (95% CI: –0.19, –0.04; p-trend = 0.005) for women with blood lead concentrations in the 
highest versus lowest quintile. In contrast, lead was not associated with walking speed in men. 
conclusion: Blood lead concentration was associated with decreased walking speed in women, but 
not in men. Our results contribute to the growing evidence that lead exposure, even at low levels, is 
detrimental to public health.
key words: environmental epidemiology, gait speed, lead, NHANES, toxicant, walking speed. 
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background correction (PerkinElmer, 
Norwalk, CT, USA). Whole blood specimens 
were processed, stored, and shipped to the 
Division of Laboratory Sciences, National 
Center for Environmental Health, Centers for 
Disease Control and Prevention (Atlanta, GA, 
USA), for analysis. Vials were stored at –20°C 
until they were shipped. The limit of detec­
tion (LOD) was 0.3 µg/dL (Miller et al. 1987; 
Parsons and Slavin 1993). NHANES quality 
assurance and quality control protocols meet 
the 1988 Clinical Laboratory Improvement 
Act mandates (Centers for Disease Control 
and Prevention 2009).
Outcome assessment. Walking speed was 
derived from the measured walk component 
of the muscle strength module completed as 
part of a medical examination at an NHANES 
mobile examination center. Measurements 
were performed by certified health techni­
cians who received intensive training on 
NHANES examination protocols (Bohannon 
2008). Subjects were asked to walk at their 
usual pace. They began with their toes behind 
a starting line. After subjects were told to start, 
timing with a hand­held stopwatch began 
when their first foot touched the floor beyond 
the start line. A 20­ft stop time was obtained 
when the first foot touched the floor beyond 
the 20­ft finish line. Walking speed has been 
shown to have excellent test–retest reliabil­
ity in several past studies (Bohannon 1997; 
Graham et al. 2008; Ostir et al. 2002).
Covariates. Demographic variables 
included age, sex, education (less than 9th 
grade, 9th–11th grade, high school gradu­
ate, some college or associate degree, college 
graduate and above), and ethnicity (Mexican 
American, other Hispanic, non­Hispanic 
white, non­Hispanic black, and other). To 
avoid identifiability, NHANES indicates 
age as 85 years for all individuals > 85 years 
of age (4.3% of our study population). 
Anthropometric covariates were standing 
height and waist circumference (categorized 
into tertiles), which are strongly associated 
with walking speed (Bohannon 2008).
Lifestyle variables were smoking (never, 
past, current), alcohol consumption (none, 
past, current light, current heavy), and 
physical activity. Participants who smoked 
≥ 100 cigarettes or a pipe or cigar ≥ 20 times 
in their lifetime were classified as current 
smokers if they reported currently smoking 
“some days” or “every day,” and were classified 
as former smokers if they currently smoked 
“not at all”; otherwise they were classified as 
never smokers. Current drinkers were classi­
fied as heavy drinkers if they consumed more 
than one drink a day (defined as a 10­oz beer, 
a 4­oz glass of wine, or 1 oz of liquor) on aver­
age, and as light drinkers if they consumed 
one drink a day or less on average. Participants 
who consumed 12 drinks in their lifetime, but 
did not consume alcohol in the past year, were 
considered past drinkers. Physical activity was 
classified according to tertiles of metabolic 
equivalents task scores based on the intensity 
and frequency of a number of physical activi­
ties reported during in the preceding 30 days 
(Ainsworth et al. 1993).
Some clinical comorbidities have been asso­
ciated with slower walking speed (Atkinson 
et al. 2007; Dumurgier et al. 2010) including 
diabetes, arthritis, and heart conditions (angina, 
myocardial infarction, coronary heart disease, 
congestive heart failure). These variables were 
considered separately because they could also be 
mediators of effects of lead exposure on walking 
speed. Participants were classified as not hav­
ing a condition if they answered “don’t know” 
when asked about their history of the condition 
(< 0.5% for any of the conditions). In addi­
tion, we adjusted for hypertension, which was 
classified based on self­reported current use of 
medication for high blood pressure, or mean 
systolic blood pressure ≥ 140 mmHg or mean 
diastolic blood pressure ≥ 90 mmHg based 
on up to four blood pressure measurements 
during the NHANES examination. In addi­
tion, we adjusted for serum homocysteine and 
C­reactive protein concentrations as biomark­
ers of tissue damage and inflammation. These 
inflammatory markers have been associated 
with slower walking speed (Albert et al. 2002; 
Kuo et al. 2006a, 2007b), but also could be 
mediators of the effects of lead.
Finally, we considered scores on the Digit 
Symbol Substitution Test (DSST) (Wechsler 
1997) as a measure of cognitive function, which 
were available for participants ≥ 60 years of age. 
Specifically, the DSST is a test of visuospatial 
and psychomotor speed that is frequently used 
as a measure of frontal lobe executive function, 
and has been negatively associated with walking 
speed (Kuo et al. 2007a).
Statistical analysis. We used SAS, ver­
sion 9.2 (SAS Institute Inc., Cary, NC, USA) 
for all analyses. We combined NHANES 
cycles using NHANES cluster design vari­
ables (SDMVSTRA, SDMVPSU) and medi­
cal examination weights (WTME­C4YR) for 
1999–2002.
We used PROC SURVEYREG to per­
form separate adjusted linear regressions for 
men and women with walking speed as the 
dependent variable. Blood lead concentration 
was divided into quintiles based on its dis­
tribution in both women and men. Analyses 
were stratified by sex because blood lead levels 
are higher in men than in women (Vahter 
et al. 2007) and men walk faster than women 
(Cooper et al. 2011). We explored pos­
sible nonlinear associations using piecewise 
regression with a 4­knot cubic spline for lead 
(STATA, version 11.0; StataCorp., College 
Station, TX, USA), but there was no evi­
dence of departure from linearity in women 
(p = 0.27) or men (p = 0.13). To reduce the 
influence of extreme exposure levels on lin­
ear trends, we tested for trend by modeling a 
continuous blood lead variable coded as the 
median value of each blood lead quintile.
Our first model (model 1) was adjusted 
for the demographic (age, sex, education, 
and ethnicity) and anthropometric vari­
ables (height and waist circumference) only, 
because these are very strongly associated with 
walking speed (Bohannon 2008). In addition, 
we conducted a model that also included 
the lifestyle variables (smoking, alcohol con­
sumption, and physical activity) (model 2); 
a model that included the demographic 
and anthropomorphic variables plus medi­
cal comorbidities (diabetes, arthritis, heart 
conditions, and hypertension) and the serum 
biomarkers of inflammation (homocysteine 
and C­reactive protein) (model 3); and a fully 
adjusted model that included all of the covari­
ates above (model 4). In addition, we con­
ducted sensitivity analyses adjusting for DSST 
score as a measure of cognitive function, and 
analyses that excluded participants with blood 
lead concentrations ≥ 10 µg/dL or ≥ 5 µg/dL.
Results
The relation between mean blood lead and 
walking speed and participants’ characteris­
tics is shown separately for women and men 
in Table 1. Study participants had a median 
age of 61.2 years (women: 62.1; men: 60.0), 
with a range of 50 to at least 85 years. Blood 
lead was lower in women (mean ± SD, 2.17 ± 
0.06 µg/dL; median, 1.72 µg/dL) than in men 
(mean, 3.18 ± 0.12 µg/dL; median, 2.41 µg/
dL). Blood lead levels tended to be higher in 
women and men who were older, non­His­
panic black, or smokers, and in those with 
lower education, higher alcohol consumption, 
and higher serum homocysteine concentra­
tions. The mean walking speed for women 
was 3.31 ± 0.03 ft/sec, and for men was 
3.47 ± 0.03 ft/sec. Walking speed tended to 
be slower in women and men who were older 
or shorter, or were smokers; in those with 
hypertension, diabetes, arthritis, or a heart 
condition; and in those with a larger waist 
circumference, lower alcohol consumption, 
lower education, higher serum  homocysteine, 
or higher C­reactive protein.
Among women, walking speed decreased 
with increasing quintiles of blood lead, and 
the highest quintile of lead was significantly 
different from the lowest based on all four 
models (Table 2). For example, in the fully 
adjusted model women in the highest quintile 
had a mean walking speed that was 0.114 ft/
sec slower (95% CI: –0.191, –0.038) than 
women in the lowest quintile (trend p­value = 
0.005). In this model, the reduction in walk­
ing speed associated with 5 more years of age 
was –0.127 ft/sec; 95% CI: –0.151, –0.104). 
Blood lead and walking speed
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Table 1. Blood lead concentration and walking speed (mean ± SD) for women and men according to demographic, anthropomorphic, lifestyle, and medical history.
Characteristics
Women Men
Participants [n (%)] Blood lead (μg/dL) Walking speed (ft/sec) Participants [n (%)] Blood lead (μg/dL) Walking speed (ft/sec)
Overall 1,798 (100) 2.17 ± 0.04 3.31 ± 0.03 1795 3.18 ± 0.08 3.47 ± 0.03
Age (years)       
50–54 308 (17.1) 1.84 ± 0.05 3.69 ± 0.06 303 (16.9) 2.79 ± 0.10 3.77 ± 0.05
55–59 213 (11.8) 1.99 ± 0.08 3.59 ± 0.06 217 (12.1) 2.74 ± 0.14 3.64 ± 0.05
60–64 354 (19.7) 2.09 ± 0.12 3.33 ± 0.05 328 (18.3) 3.28 ± 0.37 3.53 ± 0.05
65–69 271 (15.1) 2.06 ± 0.12 3.26 ± 0.06 271 (15.1) 3.02 ± 0.12 3.45 ± 0.07
70–74 246 (13.7) 2.25 ± 0.10 3.05 ± 0.07 253 (14.1) 3.34 ± 0.26 3.25 ± 0.06
75–79 162 (9.0) 2.23 ± 0.12 2.94 ± 0.08 183 (10.2) 3.02 ± 0.14 3.04 ± 0.04
≥ 80 244 (13.6) 2.50 ± 0.10 2.57 ± 0.05 240 (13.4) 3.42 ± 0.10 2.74 ± 0.05
Education     
Less than 9th grade 355 (19.8) 2.47 ± 0.15 2.67 ± 0.05 385 (21.5) 3.53 ± 0.17 3.00 ± 0.05
9th–11th grade 315 (17.6) 2.14 ± 0.12 3.06 ± 0.05 291 (16.2) 3.60 ± 0.14 3.21 ± 0.06
High school graduate 453 (25.3) 2.14 ± 0.08 3.25 ± 0.04 364 (20.3) 3.02 ± 0.10 3.38 ± 0.03
Some college or associate’s degree 424 (23.6) 1.88 ± 0.05 3.45 ± 0.04 358 (20.0) 3.03 ± 0.26 3.55 ± 0.05
College graduate and above 246 (13.7) 2.01 ± 0.08 3.78 ± 0.05 393 (21.9) 2.53 ± 0.14 3.78 ± 0.04
Ethnicity       
Mexican American 362 (21.1) 2.13 ± 0.17 3.13 ± 0.07 347 (19.3) 3.10 ± 0.15 3.22 ± 0.05
Other Hispanic 84 (4.7) 2.17 ± 0.15 2.83 ± 0.08 73 (4.1) 3.86 ± 1.37 3.29 ± 0.10
Whites (non–Hispanic) 1,010 (56.2) 2.04 ± 0.05 3.38 ± 0.04 1,066 (59.4) 2.89 ± 0.07 3.54 ± 0.03
Black (non–Hispanic) 290 (16.1) 2.42 ± 0.10 2.98 ± 0.04 272 (15.2) 4.00 ± 0.25 3.11 ± 0.04
Other 52 (2.9) 2.11 ± 0.24 3.24 ± 0.16 37 (2.1) 2.51 ± 0.21 3.28 ± 0.12
Smoking     
Never smoker 1,063 (59.3) 1.91 ± 0.05 3.28 ± 0.04 461 (25.7) 2.71 ± 0.25 3.55 ± 0.04
Past smoker 485 (27.0) 2.17 ± 0.07 3.36 ± 0.05 924 (51.6) 2.90 ± 0.07 3.48 ± 0.03
Current smoker 244 (13.6) 2.51 ± 0.09 3.31 ± 0.04 372 (20.8) 3.57 ± 0.11 3.42 ± 0.04
Alcohol use       
Never drinker 465 (26.3) 1.90 ± 0.05 3.03 ± 0.06 122 (6.9) 2.13 ± 0.17 3.34 ± 0.07
Past drinker 464 (26.2) 2.08 ± 0.08 3.22 ± 0.05 233 (13.1) 2.60 ± 0.11 3.39 ± 0.07
Current drinker light 605 (34.2) 2.03 ± 0.07 3.53 ± 0.04 790 (44.6) 2.98 ± 0.16 3.56 ± 0.03
Current drinker heavy 81 (4.6) 2.81 ± 0.18 3.66 ± 0.07 278 (15.7) 3.70 ± 0.12 3.62 ± 0.05
Height (cm)a       
Tertile 1 604 (34.0) 2.22 ± 0.08 2.99 ± 0.04 590 (33.4) 3.25 ± 0.25 3.26 ± 0.04
Tertile 2 583 (32.8) 2.09 ± 0.07 3.32 ± 0.07 587 (33.3) 3.04 ± 0.13 3.45 ± 0.05
Tertile 3 589 (33.2) 1.96 ± 0.05 3.52 ± 0.04 588 (33.3) 2.85 ± 0.07 3.66 ± 0.04
Waist circumference (cm)b       
Tertile 1 595 (33.5) 2.17 ± 0.08 3.53 ± 0.05 591 (33.4) 3.44 ± 0.23 3.53 ± 0.04
Tertile 2 595 (33.5) 2.06 ± 0.08 3.31 ± 0.05 590 (33.4) 2.88 ± 0.10 3.54 ± 0.04
Tertile 3 588 (33.1) 2.01 ± 0.06 3.09 ± 0.04 588 (33.2) 2.75 ± 0.08 3.39 ± 0.05
Homocysteine (μmol/L)c       
Tertile 1 599 (33.4) 1.78 ± 0.04 3.53 ± 0.04 598 (33.4) 2.61 ± 0.10 3.66 ± 0.04
Tertile 2 596 (33.3) 2.02 ± 0.06 3.32 ± 0.05 594 (33.2) 3.00 ± 0.18 3.48 ± 0.05
Tertile 3 596 (33.3) 2.47 ± 0.08 3.04 ± 0.06 596 (33.3) 3.52 ± 0.12 3.25 ± 0.04
C–reactive protein (mg/dL)d       
Tertile 1 612 (34.7) 2.19 ± 0.07 3.44 ± 0.05 616 (34.7) 2.76 ± 0.08 3.63 ± 0.03
Tertile 2 573 (32.5) 2.09 ± 0.06 3.33 ± 0.04 590 (33.3) 3.20 ± 0.22 3.47 ± 0.04
Tertile 3 580 (32.9) 1.94 ± 0.07 3.14 ± 0.04 567 (32.0) 3.12 ± 0.09 3.30 ± 0.04
Metabolic equivalents task scoree     
Tertile 1 752 (41.8) 2.42 ± 0.06 2.85 ± 0.05 537 (29.9) 3.47 ± 0.17 2.97 ± 0.06
Tertile 2 504 (28.0) 2.03 ± 0.06 3.31 ± 0.04 609 (33.9) 3.25 ± 0.15 3.37 ± 0.04
Tertile 3 542 (30.1) 2.09 ± 0.07 3.41 ± 0.03 649 (36.2) 3.10 ± 0.08 3.43 ± 0.03
Hypertension     
Yes 819 (45.6) 2.15 ± 0.07 3.13 ± 0.05 629 (35.0) 3.23 ± 0.12 3.35 ± 0.05
No 979 (54.4) 2.03 ± 0.04 3.43 ± 0.03 1,166 (65.0) 2.92 ± 0.11 3.53 ± 0.03
Diabetes       
Yes 256 (14.2) 2.05 ± 0.10 2.91 ± 0.06 281 (15.7) 2.39 ± 0.13 3.17 ± 0.06
No 1,542 (85.8) 2.08 ± 0.04 3.36 ± 0.03 1,514 (84.3) 3.10 ± 0.09 3.52 ± 0.03
Arthritis     
Yes 853 (47.4) 2.09 ± 0.06 3.09 ± 0.04 621 (34.6) 2.98 ± 0.10 3.37 ± 0.04
No 945 (52.6) 2.07 ± 0.05 3.50 ± 0.03 1,174 (65.4) 3.03 ± 0.11 3.54 ± 0.05
Heart condition     
Yes 227 (12.6) 2.31 ± 0.14 2.93 ± 0.08 344 (19.2) 2.87 ± 0.09 3.22 ± 0.04
No 1,571 (87.4) 2.05 ± 0.04 3.36 ± 0.03 1,451 (80.8) 3.04 ± 0.10 3.54 ± 0.03
aMean values ± SD in women and men, respectively: 160.7 ± 0.20 and 174.9 ± 0.15 cm. Tertile ranges (cm) in women and men, respectively: tertile 1, 25.6–156.4 and 136.7–156.4; tertile 2, 
156.5–162.5 and 170.1–176.4; tertile 3, 162.6–183.9 and 176.5–195.6. bMean values ± SD in women and men, respectively: 96.0 ± 0.55 and 103.4 ± 0.40 cm. Tertile ranges (cm) in women 
and men, respectively: tertile 1, 58.5–89.3 and 66.7–97.0; tertile 2, 89.4–101.8 and 97.1–107.1; tertile 3, 101.9–147.5 and 107.2–157.0. cMean values ± SD in women and men, respectively: 
9.07 ± 0.09 and 10.29 ± 0.11 μmol/L. Tertile ranges (μmol/L) in women and men, respectively: tertile 1, 1.65–7.33 and 2.97–8.61; tertile 2, 7.34–9.48 and 8.62–10.99; tertile 3, 9.49–156.3 and 
11.00–83.64. dMean values ± SD in women and men, respectively: 0.56 ± 0.02 and 0.42 ± 0.03 mg/dL. Tertile ranges (mg/dL) in women and men, respectively: tertile 1, 0.01–0.22 and 
0.01–0.14; tertile 2, 0.22–0.54 and 0.15–0.36; tertile 3 0.55–29.6 and 0.37–16.00. eMean values ± SD in women and men, respectively: 82.3 ± 75.9 and 90.2 ± 76.3 units. Tertile ranges (units) 
in women and men, respectively: tertile 1, 0–45 and 0–45; tertile 2, 16.5–82.5 and 46.0–82.5; tertile 3, 83.5–1398.0 and 83.0–1398.0.
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We found similar results when restricting 
the analyses to women with DSST scores 
(n = 1,145) and adjusting for DSST score (data 
not shown). Results were essentially unchanged 
when we excluded women with blood lead 
concentrations ≥ 10 µg/dL (n = 7, 0.4%) or 
≥ 5 µg/dL (n = 75, 4.2%) (data not shown).
For men, the model adjusted for demo­
graphic and anthropometric variables only 
(model 1) indicated a statistically significant 
linear trend (p = 0.03) toward decreasing walk­
ing speed with increasing blood lead (Table 2). 
However, this was driven by a negative asso­
ciation for the highest versus lowest quintile 
of blood lead, because there were nonsignifi­
cant increases in mean walking speeds for men 
with blood lead concentrations in the 2nd–4th 
quintiles of lead compared with the 1st. The 
negative trend was no longer significant when 
adjusted for lifestyle variables or comorbidities 
(e.g., model 4, p­trend = 0.60). In analyses 
among men with DSST scores (n = 1,115), 
further adjustment for DSST scores did not 
meaningfully change the lead results, although 
lower DSST scores were strongly associated 
with slower walking speed (data not shown). 
Results were essentially unchanged when we 
excluded men with blood lead concentra­
tions ≥ 10 µg/dL (n = 40, 2.2%) or ≥ 5 µg/dL 
(n = 263, 14.1%) (data not shown).
Discussion
We found that walking speed decreased with 
increasing blood lead concentrations among 
women, but not among men. This associa­
tion persisted with adjustment for age, educa­
tion, ethnicity, smoking, alcohol use, physical 
activity, height, waist circumference, serum 
homocysteine, serum C­reactive protein, and 
several medical comorbidities. The estimated 
reduction in mean walking speed associated 
with the highest quintile compared to the 
lowest quintile of blood lead among women 
(–0.114 ft/sec; 95% CI: –0.191, –0.038) was 
approximately equivalent to the estimated 
reduction in walking speed associated with 
5 more years of age among women in our 
NHANES data (–0.127 ft/sec; 95% CI: 
–0.151, –0.104). Based on a recent meta­
analysis of the relation between walking speed 
and mortality in populations with mean ages 
ranging from 72 to 79 years and mean walk­
ing speeds of 1.84–3.90 ft/sec (Studenski 
et al. 2011), the 0.114­ft/sec reduction in 
walking speed estimated for women in the 
highest quintile of lead would be associated 
with an approximate 4% increase in mortal­
ity, suggesting a clinically relevant difference. 
Our NHANES population had an average 
age of 61 years and an average walking speed 
of 3.39 ft/sec, consistent with the studies 
included in the meta­analysis.
There is evidence that health effects of 
 metals can differ between men and women 
(Vahter et al. 2007), though examples are lim­
ited for lead specifically. For example, among 
195 children in the Cincinnati Lead Study, 
there was a statistically significant difference by 
sex in the association between prenatal maternal 
blood lead concentrations and both attention 
and visuoconstruction test performance mea­
sured at 15–17 years, with significant nega tive 
associations seen among boys only (Ris et al. 
2004). In experimental studies, immunotoxic­
ity following lead exposure has been shown to 
be greater in female chickens and rats than in 
males (Bunn et al. 2000, 2001). An obvious 
explanation of our sex­specific effects, however, 
is not clear, and future studies should consider 
this point specifically.
Walking speed is a marker of general 
health that may reflect disturbances to the 
musculoskeletal, nervous, and cardiovascular 
systems (Abellan van Kan et al. 2009; Atkinson 
et al. 2007; Baezner et al. 2008; Buchman 
et al. 2009; Studenski et al. 2011). Clinically, 
walking speed can be used to predict life 
expectancy among older adults when coupled 
with information on age and sex (Hall 2006; 
Studenski et al. 2011). Currently, there are few 
studies of effects of environmental toxicants on 
walking speed. One previous NHANES study 
of urinary metals and walking speed reported 
that urinary cobalt, but not urinary lead, was 
associated with time to walk 20 feet (Lang 
et al. 2009). However, lead measurements in 
spot urine samples are a less reliable biomarker 
of low­level lead exposure than blood lead 
because of marked within­individual variabil­
ity (Agency for Toxic Substances and Disease 
Registry 2007; Navas­Acien et al. 2005). Past 
epidemiology studies of adults with occu­
pational exposure to lead have reported that 
blood lead concentrations are associated with 
detriments in motor performance and with 
muscle weakness (Baker et al. 1979; Bleecker 
et al. 2007; Weisskopf et al. 2004). There is 
also evidence that lead exposure at lower levels 
affects motor function, although the literature 
is more limited (Bandeen­Roche et al. 2009; 
Grashow et al. 2013; Weisskopf et al. 2007).
Lead may influence walking speed through 
several potential mechanisms. First, walking is 
often viewed as a rhythmic, simple motor task, 
but among older adults, it has been shown to 
draw upon higher­level resources, including 
executive function (Hausdorff et al. 2005). As 
a complex motor task, walking may be regu­
lated by neural networks that draw on cogni­
tive resources (Atkinson et al. 2007; Cocchini 
et al. 2004; Fitzpatrick et al. 2007; Inzitari 
et al. 2007; Rosano et al. 2005; Sheridan et al. 
2003; Soumare et al. 2009b). Lead has been 
found to be associated with worse cognitive 
function in adults, which may explain part of 
the association with walking speed (Bandeen­
Roche et al. 2009; Shih et al. 2006, 2007; 
Weisskopf et al. 2007; Weuve et al. 2009). 
However, our results did not change meaning­
fully when we adjusted for the DSST score. 
Second, lead has been associated with 
Parkinson’s disease (Coon et al. 2006; 
Table 2. Blood lead concentration in relation to walking speed.
Quintile range 
(μg/dL) Total [n (%)]
Model 1 Model 2 Model 3 Model 4
Mean change in walking 
speed (ft/sec) (95% CI) p-Value
Mean change in walking 
speed (ft/sec) (95% CI) p-Value
Mean change in walking 
speed (ft/sec) (95% CI) p-Value
Mean change in walking 
speed (ft/sec) (95% CI) p-Value
Women
0.2 to ≤ 1.2 413 (23.0) 0 (reference) — 0 (reference) — 0 (reference) — 0 (reference) —
1.3 to ≤ 1.6 348 (19.4) –0.024 (–0.115, 0.066) 0.59 –0.021 (–0.113, 0.072) 0.65 –0.026 (–0.116, 0.063) 0.55 –0.024 (–0.112, 0.064) 0.58
1.7 to ≤ 2.1 341 (19.0) –0.022 (–0.123, 0.080) 0.67 –0.018 (–0.108, 0.071) 0.68 –0.028 (–0.132, 0.077) 0.59 –0.027 (–0.118, 0.063) 0.54
2.2 to ≤ 2.9 356 (19.8) –0.067 (–0.158, 0.024) 0.14 –0.097 (–0.184, 0.009) 0.03 –0.075 (–0.165, 0.015) 0.10 –0.104 (–0.187, –0.021) 0.02
3.0 to ≤ 53.0 340 (18.9) –0.112 (–0.795, –0.029) 0.01 –0.117 (–0.191, 0.043) 0.01 –0.101 (–0.187, –0.015) 0.02 –0.114 (–0.191, –0.038) 0.01
Trend 1,798 — 0.006 — 0.002 — 0.015 — 0.005
Men
0.2 to ≤ 1.7 399 (22.2) 0 (reference) — — — 0 (reference) — 0 (reference) —
1.8 to ≤ 2.3 364 (20.3) 0.056 (–0.043, 0.156) 0.25 0.061 (–0.047, 0.172) 0.27 0.036 (–0.062, 0.135) 0.46 0.057 (–0.050, 0.165) 0.29
2.4 to ≤ 3.0 342 (19.1) 0.054 (–0.039, 0.146) 0.24 0.020 (–0.075, 0.116) 0.67 0.042 (–0.051, 0.134) 0.36 0.017 (–0.073, 0.107) 0.71
3.1 to ≤ 4.3 354 (19.7) 0.053 (–0.035, 0.142) 0.23 0.065 (–0.032, 0.162) 0.18 0.057 (–0.036, 0.150) 0.22 0.082 (–0.012, 0.175) 0.08
4.4 to ≤ 54.0 336 (18.7) –0.077 (–0.177, 0.024) 0.13 –0.047 (–0.162, 0.073) 0.43 –0.066 (–0.173, 0.041) 0.22 –0.029 (–0.154, 0.097) 0.64
Trend 1,795 — 0.03 —  0.34 — 0.10 — 0.60
Model 1: adjusted for demographic (age, education, ethnicity) and anthropometric variables (height and waist circumference). Model 2: model 1 covariates plus lifestyle variables 
(alcohol, smoking, physical activity). Model 3: model 1 covariates plus medical comorbidities and biomarkers (arthritis, diabetes, heart condition, hypertension, homocysteine, and 
C-reactive protein). Model 4: fully adjusted model.
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Weisskopf et al. 2010) and motor slowing is 
one of the hallmarks of the disease; it is possible 
that in some persons lead exposure may induce 
subtle parkinsonian signs without reaching clin­ 
ical criteria for Parkinson’s disease. Parkinson’s 
disease is rare and even less common in women 
than in men, and it is therefore unlikely that it 
accounts entirely for the association between 
lead and walking speed. 
Third, the cerebellum, a brain region that 
is involved in motor control and coordination, 
can be a target of lead toxicity. People with 
a smaller left cerebellum have been reported 
to walk slower (Rosano et al. 2007). Purkinje 
cells are the output neurons of the cerebellum, 
and lead has been shown to induce changes 
to Purkinje morphology in animal stud­ 
ies (McConnell and Berry 1979; Patrick and 
Anderson 2000). Atrophy of the cerebellum 
is associated with gait ataxia, stiff gait, and 
impaired balance and leg coordination (Morton 
and Bastian 2003); thus, toxicity of lead to the 
cerebellum may ultimately affect walking speed. 
Furthermore, electromyographic studies in 
workers have shown occupational lead exposure 
is associated with motor latencies and nerve 
conduction velocities (Yeh et al. 1995). 
Last, another potential pathway is by way 
of vascular risk factors. Lead has been found 
to be associated with kidney changes resulting 
in imbalance of the renin–angiotensin system 
(Tsaih et al. 2004), and also to alter calcium 
metabolism resulting in blood pressure eleva­ 
tion, a precursor to hypertension and cardio­ 
vascular diseases (Nash et al. 2003; Navas­Acien 
et al. 2007). These vascular health factors may 
manifest in slower walking speed (Dumurgier 
et al. 2009, 2010; Elbaz et al. 2005; Soumare 
et al. 2009b). In particular, high blood pressure 
can cause changes to white matter and neuro­ 
nal circuitry interconnecting the frontal and 
subcortical areas, regions of the brain associated 
with decision making and mood. Executive 
function, depressive symptoms, and walking 
speed have been shown to be associated with 
high blood pressure and other vascular risk fac­ 
tors in cohort of elderly community­ dwelling 
people in the Boston, Massachusetts, area 
(Hajjar et al. 2009). Additionally, peripheral 
artery disease may also modify walking speed. 
In our analyses, arthritis, diabetes, heart condi­ 
tions, and serum homocysteine and C­reactive 
protein concentrations were significant predic­ 
tors of walking speed. Adjustment for these 
comorbid conditions and biomarkers did not 
substantially alter the association with blood 
lead (model 3) in women, suggesting that the 
association is not explained solely through 
effects of lead on these factors. 
Strengths of our study include the large 
sample that is representative of the U.S. gen­ 
eral population ≥ 50 years of age, and infor­ 
mation on a multiple potential confounders. 
There are several limitations to our study as 
well. First, NHANES has a cross­sectional 
design, so we cannot make inferences about 
the temporality of exposure and outcome; in 
addition, the study does not have data on bone 
mineral density. Blood lead concentrations 
can increase as bone mineral density decreases 
because lead stored in bone is released back 
into circulation when bone is resorbed (Hu 
et al. 1998); this could create an association 
between higher blood lead and slower walk­ 
ing speed if bone loss is associated with slower 
walking speed. However, there is conflicting 
evidence for an association between changes in 
bone mineral density and walking speed, with 
several studies reporting reduced walking speed 
with greater bone loss and others no association 
(Boyer et al. 2011; Kwon et al. 2007; Lindsey 
et al. 2005; Palombaro et al. 2009; Taaffe et al. 
2003). Second, lead was measured in the blood, 
which has a half­life of roughly 1 month. We 
do not have information on long­term expo­ 
sure to lead, such as bone lead measurements 
(Hu et al. 1998). Finally, there is a potential 
for selection bias. Nonparticipation in studies 
has been found to be higher among those who 
are less healthy and with worse cognitive func­ 
tion and lower socioeconomic status (Goldberg 
et al. 2001; Launer et al. 1994; Strandhagen 
et al. 2010). However, because worse health 
and cognitive function has been associated with 
slower walking speed (Dumurgier et al. 2009; 
Hausdorff et al. 2005; Rosano et al. 2005; 
Sheridan et al. 2003; Studenski et al. 2011), 
and lower socioeconomic status is usually asso­ 
ciated with higher exposure to toxicants such as 
lead (Evans and Kantrowitz 2002), such selec­ 
tion bias would likely be in the opposite direc­ 
tion of our findings among women, but could 
contribute to the null findings among men. 
Walking speed is increasingly used as a 
simple and reliable measure of overall motor 
function in the elderly, and has been shown to 
be associated with many adverse health events 
including death (Dumurgier et al. 2009). Our 
finding of an association between higher blood 
lead concentration and decreased walking 
speed in women suggests that lead toxicity 
may contribute to neuromotor system deficits 
among the elderly. 
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